Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.

Bachelet D, Hässler S, Mbogning C, Link J, Ryner M, Ramanujam R, Auer M, Hyldgaard Jensen PE, Koch-Henriksen N, Warnke C, Ingenhoven K, Buck D, Grummel V, Lawton A, Donnellan N, Hincelin-Mery A, Sikkema D, Pallardy M, Kieseier B, Hemmer B, Hartung HP, Soelberg Sorensen P, Deisenhammer F, Dönnes P, Davidson J, Fogdell-Hahn A, Broët P; ABIRISK Consortium..

PLoS One. 2016 Nov 2;11(11):e0162752. doi: 10.1371/journal.pone.0162752.

2.

Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up.

Muris AH, Smolders J, Rolf L, Klinkenberg LJ, van der Linden N, Meex S, Damoiseaux J, Hupperts R.

PLoS One. 2016 Jun 8;11(6):e0156122. doi: 10.1371/journal.pone.0156122.

3.

The Association Between Genetic Polymorphism rs703842 in CYP27B1 and Multiple Sclerosis: A Meta-Analysis.

Jiang T, Li L, Wang Y, Zhao C, Yang J, Ma D, Guan Y, Zhao D, Bao Y, Wang Y, Yang J.

Medicine (Baltimore). 2016 May;95(19):e3612. doi: 10.1097/MD.0000000000003612.

4.

Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study.

Riccio P, Rossano R, Larocca M, Trotta V, Mennella I, Vitaglione P, Ettorre M, Graverini A, De Santis A, Di Monte E, Coniglio MG.

Exp Biol Med (Maywood). 2016 Mar;241(6):620-35. doi: 10.1177/1535370215618462.

5.

Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.

Sotirchos ES, Bhargava P, Eckstein C, Van Haren K, Baynes M, Ntranos A, Gocke A, Steinman L, Mowry EM, Calabresi PA.

Neurology. 2016 Jan 26;86(4):382-90. doi: 10.1212/WNL.0000000000002316.

PMID:
26718578
6.

Effect of vitamin D on MS activity by disease-modifying therapy class.

Rotstein DL, Healy BC, Malik MT, Carruthers RL, Musallam AJ, Kivisakk P, Weiner HL, Glanz B, Chitnis T.

Neurol Neuroimmunol Neuroinflamm. 2015 Oct 29;2(6):e167. doi: 10.1212/NXI.0000000000000167.

7.

Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls.

Bhargava P, Steele SU, Waubant E, Revirajan NR, Marcus J, Dembele M, Cassard SD, Hollis BW, Crainiceanu C, Mowry EM.

Mult Scler. 2016 May;22(6):753-60. doi: 10.1177/1352458515600248.

PMID:
26286698
8.

Increased circulating levels of vitamin D binding protein in MS patients.

Rinaldi AO, Sanseverino I, Purificato C, Cortese A, Mechelli R, Francisci S, Salvetti M, Millefiorini E, Gessani S, Gauzzi MC.

Toxins (Basel). 2015 Jan 13;7(1):129-37. doi: 10.3390/toxins7010129.

9.

Interferon beta and vitamin D synergize to induce immunoregulatory receptors on peripheral blood monocytes of multiple sclerosis patients.

Waschbisch A, Sanderson N, Krumbholz M, Vlad G, Theil D, Schwab S, Mäurer M, Derfuss T.

PLoS One. 2014 Dec 31;9(12):e115488. doi: 10.1371/journal.pone.0115488.

10.

How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms.

Reder AT, Feng X.

J Interferon Cytokine Res. 2014 Aug;34(8):589-99. doi: 10.1089/jir.2013.0158. Review.

11.

Vitamin D as an early predictor of multiple sclerosis activity and progression.

Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, Kappos L, Pohl C.

JAMA Neurol. 2014 Mar;71(3):306-14. doi: 10.1001/jamaneurol.2013.5993.

12.
13.

Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties.

Golan D, Halhal B, Glass-Marmor L, Staun-Ram E, Rozenberg O, Lavi I, Dishon S, Barak M, Ish-Shalom S, Miller A.

BMC Neurol. 2013 Jun 14;13:60. doi: 10.1186/1471-2377-13-60.

15.

Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis.

Pierrot-Deseilligny C, Souberbielle JC.

Ther Adv Neurol Disord. 2013 Mar;6(2):81-116. doi: 10.1177/1756285612473513.

16.

Biomarkers in Multiple Sclerosis: An Up-to-Date Overview.

Katsavos S, Anagnostouli M.

Mult Scler Int. 2013;2013:340508. doi: 10.1155/2013/340508.

17.

Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study.

Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Qu J, Tamaño-Blanco M, Badgett D, Tyblova M, Bergsland N, Hussein S, Willis L, Krasensky J, Vaneckova M, Seidl Z, Lelkova P, Dwyer MG, Zhang M, Yu H, Duan X, Kalincik T, Ramanathan M.

PLoS One. 2013;8(1):e53996. doi: 10.1371/journal.pone.0053996.

Items per page

Supplemental Content

Support Center